141 related articles for article (PubMed ID: 1694090)
1. Leu-19 in myeloma--a new role for an old antibody.
Wetter O; Brandhorst D; Reiter W
Eur J Cancer; 1990 Apr; 26(4):541. PubMed ID: 1694090
[No Abstract] [Full Text] [Related]
2. Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19).
Van Camp B; Durie BG; Spier C; De Waele M; Van Riet I; Vela E; Frutiger Y; Richter L; Grogan TM
Blood; 1990 Jul; 76(2):377-82. PubMed ID: 1695113
[TBL] [Abstract][Full Text] [Related]
3. Multiparameter analyses of normal and malignant human plasma cells: CD38++, CD56+, CD54+, cIg+ is the common phenotype of myeloma cells.
Leo R; Boeker M; Peest D; Hein R; Bartl R; Gessner JE; Selbach J; Wacker G; Deicher H
Ann Hematol; 1992 Mar; 64(3):132-9. PubMed ID: 1373957
[TBL] [Abstract][Full Text] [Related]
4. Establishment of a monoclonal antibody to plasma cells: a comparison with CD38 and PCA-1.
Hata H; Matsuzaki H; Matsuno F; Sonoki T; Takemoto S; Kuribayashi N; Nagasaki A; Takatsuki K
Clin Exp Immunol; 1994 May; 96(2):370-5. PubMed ID: 8187346
[TBL] [Abstract][Full Text] [Related]
5. Phenotyping primitive plasma cells.
Joshua D; Pope B; Brown R; Brown L; Murray A; Gibson J
Br J Haematol; 2002 Apr; 117(1):252-3. PubMed ID: 11918567
[No Abstract] [Full Text] [Related]
6. Detection of peripheral blood myeloma cells by three-color flow cytometry.
Witzig TE; Kimlinger TK; Greipp PR
Curr Top Microbiol Immunol; 1995; 194():3-8. PubMed ID: 7895502
[No Abstract] [Full Text] [Related]
7. Characterization of a novel interleukin-6 autocrine-dependent human plasma cell line.
Ozaki S; Wolfenbarger D; deBram-Hart M; Kanangat S; Weiss DT; Solomon A
Leukemia; 1994 Dec; 8(12):2207-13. PubMed ID: 7528862
[TBL] [Abstract][Full Text] [Related]
8. Multiple myeloma with coexpression of myeloid and natural killer cell antigens.
Drach J; Gattringer C; Huber H
Blood; 1990 Jul; 76(1):265-6. PubMed ID: 1694700
[No Abstract] [Full Text] [Related]
9. In multiple myeloma, clonotypic B lymphocytes are detectable among CD19+ peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain.
Bergsagel PL; Smith AM; Szczepek A; Mant MJ; Belch AR; Pilarski LM
Blood; 1995 Jan; 85(2):436-47. PubMed ID: 7529064
[TBL] [Abstract][Full Text] [Related]
10. The incidence of DNA aneuploidy in multiple myeloma does not correlate with stage of disease.
Nowak R; Oelschlägel U; Range U; Mölle M; Ehninger G
Am J Clin Pathol; 1998 Feb; 109(2):226-32. PubMed ID: 9583896
[TBL] [Abstract][Full Text] [Related]
11. Increased expression of natural-killer-associated and activation antigens in multiple myeloma.
Gonzalez M; San Miguel JF; Gascon A; Moro MJ; Hernandez JM; Ortega F; Jimenez R; Guerras L; Romero M; Casanova F
Am J Hematol; 1992 Feb; 39(2):84-9. PubMed ID: 1550111
[TBL] [Abstract][Full Text] [Related]
12. [Myeloma precursor cells].
Iwato K; Kawano MM
Rinsho Ketsueki; 1993 Apr; 34(4):433-8. PubMed ID: 7685432
[TBL] [Abstract][Full Text] [Related]
13. Multiple myeloma: expression of nucleoside transporters on malignant plasma cells and their relationship to cellular proliferation.
Petersen AJ; Brown RD; Pope BB; Jamieson GP; Paterson AR; Gibson J; Wiley JS; Joshua DE
Leuk Lymphoma; 1994 May; 13(5-6):491-9. PubMed ID: 8069194
[TBL] [Abstract][Full Text] [Related]
14. The clonal hierachy in multiple myeloma.
Rasmussen T; Jensen L; Johnsen HE
Acta Oncol; 2000; 39(7):765-70. PubMed ID: 11145430
[TBL] [Abstract][Full Text] [Related]
15. Multiple myeloma: relationship between light chain isotype suppression, labelling index of plasma cells, and CD38 expression on peripheral blood lymphocytes.
Joshua DE; Ioannidis R; Brown R; Francis SE; Gibson J; Kronenberg H
Am J Hematol; 1988 Sep; 29(1):5-11. PubMed ID: 3052044
[TBL] [Abstract][Full Text] [Related]
16. Increased expression of CD56 and HLA/DR antigens in CD2+ cells from multiple myeloma patients.
Lapeña P; Prieto A; Garcia-Suarez J; Reyes E; San Miguel J; Jorda J; Alvarez-Mon M
Am J Hematol; 1994 Jun; 46(2):158-9. PubMed ID: 7513496
[No Abstract] [Full Text] [Related]
17. Expression of the hematopoietic stem cell antigen CD34 on blood and bone marrow monoclonal plasma cells from patients with multiple myeloma.
Kimlinger T; Witzig TE
Bone Marrow Transplant; 1997 Mar; 19(6):553-6. PubMed ID: 9085734
[TBL] [Abstract][Full Text] [Related]
18. Soluble urokinase-type plasminogen activator receptor (suPAR) as an independent factor predicting worse prognosis and extra-bone marrow involvement in multiple myeloma patients.
Rigolin GM; Tieghi A; Ciccone M; Bragotti LZ; Cavazzini F; Della Porta M; Castagnari B; Carroccia R; Guerra G; Cuneo A; Castoldi G
Br J Haematol; 2003 Mar; 120(6):953-9. PubMed ID: 12648064
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of CD38 as target for immunotherapy in multiple myeloma.
Vooijs WC; Schuurman HJ; Bast EJ; de Gast GC
Blood; 1995 Apr; 85(8):2282-4. PubMed ID: 7718903
[No Abstract] [Full Text] [Related]
20. Preliminary studies for an immunotherapeutic approach to the treatment of human myeloma using chimeric anti-CD38 antibody.
Stevenson FK; Bell AJ; Cusack R; Hamblin TJ; Slade CJ; Spellerberg MB; Stevenson GT
Blood; 1991 Mar; 77(5):1071-9. PubMed ID: 1995092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
